Behind The Idea #5: Gilead's Hunt And The Crispr Crapshoot
Mergers a Acquisitions (MaA) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen. Learn more about your ad choices. Visit megaphone.fm/adchoices
